Management Presentation: Biosimilar Pipeline and Margin Improvement Strategy
Creating the #1 European Generics company and a global leader in
Biosimilars
100% spin-off
New Sandoz shares issued to existing
Novartis Shareholders
Investment grade
credit rating
Targeted from rating agencies
SIX Swiss Exchange
listing
Switzerland
Complemented by an American Depository
Receipt (ADR) Level 1 program in the US
Incorporated and headquartered
On or around
04 October 2023
24 October 2023
Planned spin-off on track¹
Sandoz nine-months sales 2023
1. Completion of the transaction is subject to certain conditions, including consultation with works councils and employee representatives (as required), general market conditions, tax rulings and opinions, final Board of Directors endorsement
and shareholder approval in line with Swiss corporate law
30
Management Presentation
SANDOZView entire presentation